LUMIVANCE Trademark

Trademark Overview

On Wednesday, February 19, 2020, a trademark application was filed for LUMIVANCE with the United States Patent and Trademark Office. The USPTO has given the LUMIVANCE trademark a serial number of 88802663. The federal status of this trademark filing is REGISTERED as of Tuesday, March 2, 2021. This trademark is owned by Commave Therapeutics SA. The LUMIVANCE trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products for the treatment of attention deficit and hyperactivity disorder (ADHD)
lumivance

General Information

Serial Number88802663
Word MarkLUMIVANCE
Filing DateWednesday, February 19, 2020
Status700 - REGISTERED
Status DateTuesday, March 2, 2021
Registration Number6280320
Registration DateTuesday, March 2, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 15, 2020

Trademark Statements

Goods and Servicespharmaceutical products for the treatment of attention deficit and hyperactivity disorder (ADHD)

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 24, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCommave Therapeutics SA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGeneva 1202
CH
Party NameCommave Therapeutics SA
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGeneva 1202
CH
Party NameCommave Therapeutics SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGeneva 1202
CH

Trademark Events

Event DateEvent Description
Tuesday, July 20, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 20, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 20, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 2, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, December 15, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 15, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 25, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, November 6, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 6, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 6, 2020NON-FINAL ACTION E-MAILED
Friday, November 6, 2020NON-FINAL ACTION WRITTEN
Thursday, November 5, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 30, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 10, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 10, 2020NON-FINAL ACTION E-MAILED
Wednesday, June 10, 2020NON-FINAL ACTION WRITTEN
Friday, June 5, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 2, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 11, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 11, 2020NON-FINAL ACTION E-MAILED
Monday, May 11, 2020NON-FINAL ACTION WRITTEN
Friday, May 8, 2020ASSIGNED TO EXAMINER
Monday, March 9, 2020PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Saturday, February 29, 2020ASSIGNED TO LIE
Tuesday, February 25, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, February 24, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, February 22, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

lumivance hyperactivity disorder adhd deficit attention products treatment pharmaceutical